Albany Molecular Research (AMRI) Posts Q3 adj.-Loss of $0.12, Misses Views; Guides Q410, FY10

Article Stock Quotes (1) Comments (0)

Albany Molecular Research, Inc. (Nasdaq: AMRI) reports Q3 adjusted loss of $0.12, versus the consensus of ($0.08.) Revenue for the quarter came in at $50.6 million, compared to the consensus of $51.06 million.

Sees Q410 contract revs of $40 - $43 million with an adjusted loss per share of $0.17 - $0.14. Consensus sees revs of $59.31 and an EPS of $0.02.

Sees FY10 contract revs of $162 - $166 million and an adjusted loss per share of $0.21 - $0.18. Consensus sees revs of $209.18 million and an EPS of $0.12.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
• Nordson Corp (NDSN) Reports In-Line Q2 EPS, Q3 Guidance Falls Short
• Pandora (P) Pops Higher on Q1 Results; Expands Listener Base by 2.5M Subs

Create E-mail Alert Related Categories

Earnings, Guidance

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?